Trial intelligence / Profile preview

Apatinib plus docetaxel-based chemotherapy for conversion therapy in unresectable adenocarcinoma of the esophagogastric junction

ChiCTR-OIN-17012575Phase 2Recruiting

Sponsor
First Affiliated Hospital of Nanchang University
Start
Dec 2016
Modality
Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 2, open-label trial of Rivoceranib, docetaxel, fluorouracil and folinic acid in Esophago-Gastric Adenocarcinoma (2 arms), sponsored by First Affiliated Hospital of Nanchang University. Primary endpoint: R0 resection rate. Started Dec 2016; status: recruiting.

02

Drugs

Rivoceranibdocetaxelfluorouracilfolinic acid
03

Conditions

Esophago-Gastric Adenocarcinoma

Beyond the preview

Go deeper on ChiCTR-OIN-17012575.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR-OIN-17012575.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call